Recursion Pharmaceuticals FY Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Event**: Second annual Guggenheim Healthcare Innovation Conference - **Date**: November 11, 2025 - **Key Speakers**: Najat Khan (incoming CEO), Ben Taylor (CFO) Key Points Leadership Transition - Najat Khan will take over as CEO starting January 1, 2026, marking a planned transition to enhance company leadership continuity [2][3] - Chris, the outgoing CEO, will remain on the board as chair and serve as an executive advisor [2] Strategic Focus and Evolution - The company is transitioning from exploring AI's potential in drug discovery to demonstrating proof of impact [2][4] - Emphasis on increasing shareholder value and patient impact through a strengthened pipeline and strategic partnerships [5][6] Partnerships and Collaborations - Significant partnerships with Roche and Sanofi, with milestones worth approximately $300 million per program [5][6] - Collaboration with MIT and use of advanced supercomputing capabilities to enhance data analysis [9][10] - Over $500 million in partnership inflows, indicating strong investor interest and validation of the platform [12][13] Pipeline and Therapeutic Areas - Focus on four therapeutic areas: oncology, rare diseases, neuroscience, and gastrointestinal oncology [24] - Intentional targeting of novel and challenging drug targets in oncology, including RBM39 and CDK7 [25][26] - Development of a comprehensive clinical development platform for patient selection and trial acceleration [27] CDK7 Inhibitor Development - CDK7 inhibitors show manageable gastrointestinal toxicity with a 7% discontinuation rate and no severe adverse events [29] - Early signs of efficacy observed in monotherapy, with ongoing combination studies in ovarian cancer [31] Financial Position and Future Outlook - Cash position reported at nearly $800 million, sufficient to fund operations through year-end 2027 without additional financing [41] - Anticipation of at least $100 million in partner inflows by year-end 2026, with multiple clinical milestones expected [42][43] Integration with Exscientia - Successful integration of technology platforms with a focus on operational efficiency, achieving a 35% reduction in expenses [17][18] - Retention of cultural and operational capabilities from both legacy companies [19][20] Upcoming Milestones - Key upcoming events include data readouts for the FAP program, which has shown significant polyp burden reduction in trials [36][43] - Continued focus on rapid decision-making regarding pipeline programs to optimize capital allocation [43] Conclusion Recursion Pharmaceuticals is positioned for growth with a strong leadership transition, strategic partnerships, and a robust pipeline focused on innovative therapeutic areas. The company aims to leverage its AI-driven platform to deliver differentiated therapeutics while maintaining a solid financial foundation.